{
    "ticker": "ABCL",
    "name": "AbCellera Biologics Inc.",
    "description": "AbCellera Biologics Inc. is a biotechnology company that specializes in the discovery and development of monoclonal antibodies for therapeutic use. Founded in 2012 and headquartered in Vancouver, Canada, AbCellera leverages its proprietary technology platform to analyze natural immune responses and identify high-quality antibodies that can be engineered into effective therapeutic candidates. The company gained significant attention for its rapid response to the COVID-19 pandemic, where it played a pivotal role in the development of treatments derived from antibodies. AbCellera's mission is to transform the way therapeutics are discovered and developed, aiming to make the process faster and more efficient. The company collaborates with leading pharmaceutical and biotechnology companies to accelerate the development of new therapies for various diseases, including cancer, autoimmune disorders, and infectious diseases. AbCellera\u2019s innovative approach combines advanced machine learning techniques with extensive biological data, enabling more precise and effective drug development. As a leader in the biotechnology field, AbCellera is committed to improving patient outcomes through its groundbreaking research and development efforts.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Vancouver, Canada",
    "founded": "2012",
    "website": "https://www.abcellera.com",
    "ceo": "Carl Hansen",
    "social_media": {
        "twitter": "https://twitter.com/AbCellera",
        "linkedin": "https://www.linkedin.com/company/abcellera/"
    },
    "investor_relations": "https://investors.abcellera.com",
    "key_executives": [
        {
            "name": "Carl Hansen",
            "position": "CEO"
        },
        {
            "name": "Lindsay R. B. Sutherland",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Monoclonal Antibodies",
                "COVID-19 Treatments"
            ]
        },
        {
            "category": "Technology Platforms",
            "products": [
                "Antibody Discovery Platform"
            ]
        }
    ],
    "seo": {
        "meta_title": "AbCellera Biologics Inc. | Innovating Antibody Discovery",
        "meta_description": "Discover AbCellera Biologics Inc., a leader in antibody discovery and development. Explore our innovative technology and commitment to improving patient outcomes.",
        "keywords": [
            "AbCellera",
            "Biotechnology",
            "Monoclonal Antibodies",
            "Therapeutics",
            "COVID-19 Treatments",
            "Antibody Discovery"
        ]
    },
    "faq": [
        {
            "question": "What does AbCellera do?",
            "answer": "AbCellera specializes in the discovery and development of monoclonal antibodies for therapeutic use."
        },
        {
            "question": "Who is the CEO of AbCellera?",
            "answer": "Carl Hansen is the CEO of AbCellera Biologics Inc."
        },
        {
            "question": "Where is AbCellera headquartered?",
            "answer": "AbCellera is headquartered in Vancouver, Canada."
        },
        {
            "question": "What are AbCellera's main products?",
            "answer": "AbCellera's main products include monoclonal antibodies and COVID-19 treatments."
        },
        {
            "question": "When was AbCellera founded?",
            "answer": "AbCellera was founded in 2012."
        }
    ],
    "competitors": [
        "REGN",
        "AMGN",
        "MRNA",
        "BMRN"
    ],
    "related_stocks": [
        "NVAX",
        "PFE",
        "JNJ",
        "GILD"
    ]
}